Oncology departments are increasingly integrating broad-panel liquid biopsies into routine patient evaluations, reducing reliance on invasive tissue samplings and accelerating treatment timelines.
Genomic Sequencing Scale
Reductions in next-generation sequencing costs have rendered high-depth cell-free DNA analysis economically viable for health systems, allowing detection of micro-metastases months before conventional imaging.
Reimbursement Dynamics
Insurers are expanding coverage criteria as longitudinal studies demonstrate that early targeted therapy intervention based on liquid biopsy results reduces long-term hospitalization expenditure.